α-Bisabolol / Chamomile oil / Dose Cancer Research Results

BSB, α-Bisabolol / Chamomile oil: Click to Expand ⟱
Features:

α-Bisabolol — α-Bisabolol is a naturally occurring monocyclic sesquiterpene alcohol best known as a major bioactive constituent of chamomile essential oil, especially German chamomile (Matricaria chamomilla / Matricaria recutita) and related chamomile preparations. It is a small lipophilic phytochemical classified as a plant-derived essential-oil terpene alcohol, with common abbreviations including α-BSB, BSB, and levomenol for the (-)-α-bisabolol enantiomer. In oncology research it is mainly a preclinical pro-apoptotic and anti-invasive compound with preferential mitochondrial stress effects in cancer models; in clinical deployment it remains a cosmetic/natural-health constituent rather than an approved anticancer drug.

-The main components in German chamomile are terpenoid; α-bisabolol and its oxide azulenes, such as chamazulene (1–15%); and apigenin. Roman chamomile, on the other hand, contains mainly angelic acid and tiglic acid esters. Apigenin is a main bioactive component and considered a quality marker of chamomile.

Primary mechanisms (ranked):

  1. Mitochondria-centered apoptosis through mitochondrial membrane depolarization, permeability transition pore involvement, oxygen-consumption disruption, and downstream caspase activation.
  2. Membrane/lipid-raft-mediated cellular uptake and organelle accumulation, contributing to preferential toxicity in malignant cells with altered membrane and mitochondrial physiology.
  3. Suppression of migration, invasion, and adhesion-associated signaling in selected cancer models, including pancreatic and lung cancer cell systems.
  4. PI3K/AKT and NF-κB pathway suppression in selected models, with context-dependent reduction of survival and inflammatory signaling.
  5. Radiosensitization or chemosensitization in limited preclinical settings, including XIAP/caspase-3-associated enhancement of radiation-induced apoptosis and reported interactions with standard cytotoxic stress models.
  6. ROS/redox modulation as a secondary, context-dependent axis: antioxidant/anti-inflammatory in normal inflammatory models, but pro-death mitochondrial stress may dominate in susceptible cancer cells.

Bioavailability / PK relevance: α-Bisabolol is highly lipophilic and poorly water soluble, so systemic translation depends strongly on formulation, route, dose, and vehicle. Essential-oil or neat-compound exposure does not imply predictable plasma exposure, and advanced delivery systems such as cyclodextrin complexes, nanoemulsions, or lipid carriers may be required for reproducible systemic or CNS delivery.

In-vitro vs systemic exposure relevance: Most anticancer findings use direct in-vitro exposure at micromolar to high-micromolar concentrations, often with solvent-assisted delivery. These concentrations may exceed achievable free systemic exposure after ordinary chamomile tea, dietary chamomile, or topical/cosmetic use. Chamomile oil composition is also chemotype-dependent, so α-bisabolol content can vary substantially.

Clinical evidence status: Cancer evidence is preclinical only. There are human trials of α-bisabolol-containing topical products for non-cancer indications, and chamomile has natural-health/traditional-use monographs for digestive, inflammatory gastrointestinal, and calmative uses, but there is no established human oncology indication, no approved anticancer label, and no cancer RCT evidence for α-bisabolol or chamomile oil.

Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondria / MPTP ↑ MPTP opening, ↓ mitochondrial membrane potential, ↓ oxygen consumption ↔ or lower sensitivity (model-dependent) R/G Intrinsic apoptosis Core anticancer mechanism; supported most strongly in glioma and other transformed-cell models.
2 Caspase apoptosis / XIAP ↑ caspase-3 activity, ↓ XIAP restraint (model-dependent) ↔ or protective inflammatory modulation (context-dependent) G Execution-phase apoptosis Important for radiation-enhanced apoptosis in endometrial cancer cells and general pro-apoptotic activity.
3 Lipid rafts / organelle entry ↑ lipid-raft-mediated uptake and intracellular delivery ↔ (model-dependent) P/R Preferential intracellular accumulation Likely upstream determinant of selective mitochondrial and lysosomal stress.
4 Cell migration / invasion ↓ motility, ↓ invasion, ↓ invasive phenotype ↔ G Anti-metastatic phenotype Reported in pancreatic cancer and lung cancer models; therapeutically interesting but still preclinical.
5 PI3K / AKT survival signaling ↓ PI3K/AKT signaling (model-dependent) ↔ or mixed G Reduced survival signaling Secondary/contextual mechanism; not yet a clean validated primary target axis.
6 NF-κB / inflammatory signaling ↓ NF-κB-associated survival or inflammatory signaling (model-dependent) ↓ inflammatory cytokine signaling G Anti-inflammatory and pro-apoptotic context shift May be protective in normal inflammatory tissue while reducing survival signaling in some cancer models.
7 ROS / redox stress ↑ mitochondrial stress or mixed ROS effects (context-dependent) ↓ oxidative/inflammatory stress (context-dependent) R/G Context-dependent redox modulation Not a simple pro-oxidant; antioxidant and anti-inflammatory effects are common outside cancer models.
8 NRF2 / antioxidant response ↔ or mixed (model-dependent) ↑ antioxidant defense reported in some injury models G Secondary cytoprotection Include as secondary only; not the central anticancer mechanism for α-bisabolol.
9 Radiosensitization ↑ radiation-induced apoptosis (requires external trigger) Unknown; possible normal-tissue protection in inflammatory injury models G Adjunct sensitization Promising but narrow evidence base; not clinically established.
10 Chemosensitization ↑ cytotoxic stress response (model-dependent) Potential tissue-protective effects in doxorubicin injury models G Adjunct interaction Direction may differ by tissue: anticancer sensitization versus normal-organ protection requires careful separation.
11 Clinical Translation Constraint Direct in-vitro exposure may not match systemic exposure Safety generally favorable but allergy and formulation constraints remain G Bioavailability and evidence limitation Poor aqueous solubility, variable chamomile-oil composition, limited PK data, and lack of oncology trials are the main constraints.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr



Alzheimer’s disease relevance: α-Bisabolol has meaningful preclinical AD relevance through amyloid-β toxicity reduction, mitochondrial protection, anti-inflammatory activity, oxidative-stress reduction, and possible cholinesterase-related effects. Evidence includes Aβ-induced cell and animal/C. elegans models, scopolamine-memory models for α-bisabolol derivatives, and chamomile essential-oil studies with α-bisabolol-rich composition. However, there is no established human AD clinical evidence for α-bisabolol, and brain exposure is likely formulation-dependent because the compound is lipophilic and poorly water soluble.
Dose, Dosage: Click to Expand ⟱
Source:
Type:
Drug dosage vs efficacy, and actual dosage number of research papers.
Scientific Papers found: Click to Expand⟱
6556- BSB,    A Comprehensive Study of Therapeutic Applications of Chamomile
- Review, Nor, NA - Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, *antiOx↑, *AntiBio↑, *hepatoP↑, *AntiCan↑, *other↝, *toxicity↓, *Wound Healing↓, *Dose↝, *Dose↝, *eff↝, *ROS↓, *TNF-α↓, *IL6↓, *other↝, *AST↓, *ALAT↓,
6552- BSB,    Biochemical characterization of chamomile essential oil: Antioxidant, antibacterial, anticancer and neuroprotective activity and potential treatment for Alzheimer's disease
- in-vivo, AD, NA
*TNF-α↓, *Aβ↓, *Casp3↓, *Bcl-2↓, *neuroP↑, *antiOx↑, *Inflam↓, *AntiBio↑, *AChE↓, *BChE↓, Dose↝, Dose↝, Dose↝,
6549- BSB,    (-)-α-bisabolol prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice
- in-vivo, Nor, NA
*antiOx↑, Inflam↓, *Dose↝, *neuroP↑, *motorD↑, *memory↑, *MPO↓, *TNF-α↓, *iNOS↓,
6548- BSB,    Anticancer effects of α-Bisabolol in human non-small cell lung carcinoma cells are mediated via apoptosis induction, cell cycle arrest, inhibition of cell migration and invasion and upregulation of P13K/AKT signalling pathway
- in-vitro, NSCLC, A549
AntiCan↑, Dose↝, TumCCA↑, mt-Apoptosis↑, TumCMig↓, PI3K↓, Akt↓,
6547- BSB,    Antitumor effects of a-bisabolol against pancreatic cancer
- vitro+vivo, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vitro, PC, KLM1 - in-vitro, PC, KP4 - in-vitro, Nor, ACBRI515
TumCP↓, selectivity↑, Apoptosis↑, Akt↓, EGR1↑, TumCG↓, Dose↝, PI3K↓, PDK1↓, mTORC2↑,
6545- BSB,    The antineoplastic agent α-bisabolol promotes cell death by inducing pores in mitochondria and lysosomes
MPT↑, Casp↑, TumAuto↑, Apoptosis↑, TumCD↑, Dose↝, MMP↓, ROS↑, mtDam↑,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   MPT↑, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

PDK1↓, 1,  

Cell Death ⓘ

Akt↓, 2,   Apoptosis↑, 2,   mt-Apoptosis↑, 1,   Casp↑, 1,   TumCD↑, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

mTORC2↑, 1,   PI3K↓, 2,   TumCG↓, 1,  

Migration ⓘ

TumCMig↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

EGR1↑, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 6,   selectivity↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,  
Total Targets: 22

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

AntiBio↑, 2,  

Redox & Oxidative Stress ⓘ

antiOx↑, 3,   MPO↓, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,  

Cell Death ⓘ

Bcl-2↓, 1,   Casp3↓, 1,   iNOS↓, 1,  

Transcription & Epigenetics ⓘ

other↝, 2,  

Immune & Inflammatory Signaling ⓘ

IL6↓, 1,   Inflam↓, 2,   TNF-α↓, 3,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BChE↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 3,   eff↝, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   hepatoP↑, 1,   memory↑, 1,   motorD↑, 1,   neuroP↑, 2,   toxicity↓, 1,   Wound Healing↓, 1,  
Total Targets: 27

Scientific Paper Hit Count for: Dose, Dosage
6 α-Bisabolol / Chamomile oil
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:413  Target#:1114  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page